US FDA Outlines Wishlist For Decentralized Clinical Trials
Companies Need Not Have An ‘All Or Nothing’ Approach
Executive Summary
As interest in conducting remote decentralized clinical trials grows, a senior US regulator explains what companies should consider when planning such trials.
You may also be interested in...
New Global Alliance To Drive Momentum On Decentralized Trials
A new multi-stakeholder alliance wants to improve the adoption of decentralized clinical trials that have already drawn much attention during the COVID-19 pandemic. There are plans to aggregate best practices, share evidence and information, and identify and address key barriers.
Decentralized Trials Guidance May Reflect US FDA’s Lessons Learned During COVID-19
Work on guidance that was originally expected in 2020 continues as the agency and industry learn more about the utility and spectrum of decentralized trials as a result of the novel coronavirus pandemic.
COVID-19 Trial Changes Are "Propulsive Force" For Digital Adoption
Robert Califf, a former FDA commissioner turned Verily Life Sciences exec, is just one of the voice predicting a long-term impact on clinical trial processes from the COVID-19 outbreak.